全球胰岛淀粉样肽类似物市场 – 行业趋势和 2029 年预测

 市场分析和规模

近年来，由于糖尿病患病率不断上升，预计预测期内胰岛淀粉样多肽类似物市场将快速增长。胰岛淀粉样多肽是一种由胰腺β细胞产生的肽类激素，因此糖尿病患者缺乏这种激素。这种激素通过延迟胃排空来促进饱腹感。它还有助于胰岛素控制餐后升高的血糖水平。胰岛淀粉样多肽类似物是用于治疗 I 型和 II 型糖尿病的注射药物。因此，这导致市场对胰岛淀粉样多肽类似物的需求量很大。

Data Bridge Market Research 分析称，2021 年胰淀素类似物市场价值为 5.2275 亿美元，预计到 2029 年将达到 7.9619 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 5.40%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

市场定义

糖尿病可用胰岛淀粉样多肽类似物治疗。胰岛淀粉样多肽和胰岛淀粉样多肽类似物具有与生理胰岛淀粉样多肽相似的特性。胰岛淀粉样多肽类似物在进餐前皮下注射。它们是稳定的合成化学物质。胰腺的β细胞与胰岛素一起分泌胰岛淀粉样多肽。胰岛淀粉样多肽是一种由37个氨基酸组成的多肽神经内分泌激素，可抑制食物摄入、延迟胃排空、通过肾素-血管紧张素系统调节血压，并抑制胰高血糖素分泌，让人感觉饱腹或完全饱足。

报告范围和市场细分

Amylin Analog? Market Dynamics

Drivers

• Increasing prevalence of diabetes

The rising prevalence of diabetes is a primary driver of the amylin analog? market's growth. A major reason driving the growth of the amylin analogues market is the growing burden of diabetes on industrialised economies around the world, as a result of their role as global players, and the consequent demand for sophisticated therapeutic medications to treat it.  

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of amylin analog? market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness about diabetes, its type, treatment and causes will expand the amylin analog? market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of amylin analog? market. Along with this, rising geriatric population and surging prevalence of obesity will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the amylin analog? market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

• Rising adoption rate of e-commerce

Using e-commerce as an alternative to traditional pharmacy stores during COVID-19 and beyond is anticipated to boost sales of amylin analogues since an Omni channel strategy can give customers with service levels that exceed their expectations. This will further enhance the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the amylin analog? market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the amylin analog? market. Additionally, strict guidelines as well as regulations and side effects of amylin analog? such as headache, nausea, vomiting, low blood sugar and others will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This amylin analog? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the amylin analog? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Amylin analog? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Amylin Analog? Market

Pharmaceutical sector in coordination with governments are trying to combat the COVID-19 pandemic, from vaccine development to pharmaceutical supply chain planning. Furthermore, hydroxychloroquine regularly used medications have seen a tremendous increase for the treatment of COVID-19. Due to the enormous demand for these treatments, manufacturers of COVID-19 management drugs have a lot of prospects, as many wealthy countries are running out of them. As a consequence of the large requirement for vaccines as well as treatment medications for COVID-19, the pharmaceutical and biotechnology sector are anticipated to rise significantly in the coming years. Hence, the market for amylin analogues is projected to be significantly impacted.

Recent Development

• In November 2021, Zealand Pharma had announced the first subject dosed in Phase 1 trial of amylin analogue ZP8396 for the treating of obesity. ZP8396 is a strong long-acting amylin analogue that has been developed to improve solubility, reduce fibrillation, and allow co-formulation with other peptides, particularly GLP-1 analogues. Amylin analogues have the potential to be used as single or combined treatments for obesity.

全球胰岛淀粉样肽类似物?市场范围

胰岛淀粉样多肽类似物市场根据糖尿病类型、药物类型、剂量、给药途径、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

糖尿病类型

• I 型糖尿病
• II 型糖尿病
• 妊娠糖尿病

根据糖尿病类型，全球肝病药物市场分为 I ​​型糖尿病、II 型糖尿病和妊娠期糖尿病。

药物类型

• 普兰林肽
• 其他的

根据药物类型，全球肝病药物市场分为普兰林肽和其他药物。

剂量

• 注射剂
• 其他的

根据剂量，胰岛淀粉样多肽类似物市场分为注射剂和其他剂型。  

给药途径

• 皮下
• 其他的

胰岛淀粉样多肽类似物市场的给药途径部分分为皮下给药和其他给药途径。

 最终用户

• 医院
• 专科诊所
• 家庭护理
• 其他的

根据最终用户，胰淀素类似物市场分为医院、专科诊所、家庭护理和其他。

分销渠道

• 医院药房
• 零售药店
• 网上药店
• 其他的

根据分销渠道，胰淀素类似物市场也细分为医院药房、零售药房、网上药房和其他。

Amylin 类似物?市场区域分析/见解

对 Amylin 类似物市场进行了分析，并按国家、糖尿病类型、药物类型、剂量、给药途径、最终用户和分销渠道提供了市场规模见解和趋势，如上所述。

Amylin 类似物？市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、巴西、阿根廷和南美洲的其他地区（南美洲）

北美在胰岛淀粉样多肽类似物市场占据主导地位，因为该地区糖尿病患者数量不断增加。此外，肥胖患病率的上升和主要关键参与者的不断增加将进一步推动该地区市场的增长率。

由于医疗保健支出增加和医疗保健基础设施改善，预计亚太地区在预测期内将实现增长。此外，肥胖症患病率的上升将进一步推动该地区市场的增长率

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和胰淀素类似物市场份额分析

Amylin 类似物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对 Amylin 类似物市场的关注有关。

在胰岛淀粉样多肽类似物市场运营的一些主要参与者是：

• 阿斯利康（英国）
• 勃林格殷格翰国际有限公司（德国）
• 赛诺菲（法国）
• 诺和诺德公司（丹麦）
• 百时美施贵宝公司 (美国)
• Biocon（印度）    

SKU-68112